Rachel Rogers

Disclosure(s): Gilead Sciences, Inc.: Employee; Medical writing support provided by Aspire Scientific (Bollington, UK), Stocks/Bonds (Private Company)

Poster(s):

• (P-529) Comparison of Renal Outcomes by Tenofovir Alafenamide Fumarate (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-550) Efficacy and Safety of B/F/TAF in Black Adults with HIV Who Are Treatment Naïve: 5-Year Follow-Up from Two Phase 3 Studies
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT